The world market for vaccines will be valued at $33.8 billion in 2012, a report by Visiongain has revealed.
Paediatric vaccination continues to dominate the market, but the increased immunisation of adults and the growth of therapeutic vaccines used in cancer treatment are set to drive revenue through to 2022, the study suggests.
Published in July, the World Vaccines Market 2012-2022 report predicts revenues of leading vaccines including Pfizer's Prevnar-13 for the prevention of pneumonia; Gardasil, developed by Merck to prevent the human papillomavirus; and Sanofi Pasteur's influenza vaccine, Fluzone.
Visiongain pharmaceutical industry analyst Dr James Evans said, "Pfizer's Prevnar-13, the biggest vaccine franchise in the world in 2011 with sales of $3.7bn, is soon to be extended to adults. It's the first multi-billion dollar vaccine franchise, and it will replace Lipitor as Pfizer's biggest product.
"That's a symbolic moment: vaccines are joining other biological products as the main driver for the pharmaceutical industry overall. The expansion of the therapeutic vaccines segment will accelerate that process, with vaccine treatments for melanoma, ovarian and lung cancers in the next ten years," added Evans.
Image: Leading vaccines like Sanofi's Fluzone (pictured) is expected to drive revenue growth in 2012.